Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Actavis
February 05, 2013 16:30 ET
|
Somaxon Pharmaceuticals, Inc.
SAN DIEGO, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with...
Somaxon Announces That Paladin Labs Has Received Approval of New Drug Submission for Silenor (R) in Canada
December 17, 2012 16:35 ET
|
Somaxon Pharmaceuticals, Inc.
SAN DIEGO, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced that its licensee Paladin Labs Inc. (TSX:PLB) has received approval from Health Canada of...
Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc.
December 11, 2012 07:00 ET
|
Somaxon Pharmaceuticals, Inc.
Somaxon Shareholders to Receive $25 Million in Pernix Common Stock
Pernix Management to Host a Conference Call Today at 9:00 a.m. EST
THE WOODLANDS, Texas, and SAN DIEGO, Dec. 11, 2012 (GLOBE...
Somaxon Pharmaceuticals Reports Third Quarter 2012 Financial Results
October 31, 2012 16:00 ET
|
Somaxon Pharmaceuticals, Inc.
Conference call scheduled today at 4:30 p.m. ET (1:30 p.m. PT);
Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO, Oct. 31, 2012 (GLOBE NEWSWIRE) -- Somaxon...
Somaxon Pharmaceuticals to Report Third Quarter 2012 Results and Conduct Conference Call on Wednesday, October 31
October 22, 2012 16:30 ET
|
Somaxon Pharmaceuticals, Inc.
SAN DIEGO, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it will release its financial results for the third...
Somaxon Pharmaceuticals Approves 1-for-8 Reverse Stock Split and Decrease in the Number of Authorized Shares of Its Common Stock to 25,000,000 Shares
October 11, 2012 08:05 ET
|
Somaxon Pharmaceuticals, Inc.
SAN DIEGO, Oct. 11, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that its Board of Directors approved a 1-for-8 reverse...
Somaxon Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
August 27, 2012 16:30 ET
|
Somaxon Pharmaceuticals, Inc.
SAN DIEGO, Aug. 27, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon's president and chief...
Somaxon Pharmaceuticals Reports Second Quarter 2012 Financial Results
August 07, 2012 16:00 ET
|
Somaxon Pharmaceuticals, Inc.
Conference Call Scheduled Today at 4:30 p.m. ET (1:30 p.m. PT);
Simultaneous Webcast at http://investors.somaxon.com/eventdetail.cfm
SAN DIEGO, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Somaxon...
Somaxon Pharmaceuticals to Report Second Quarter 2012 Results and Conduct Conference Call on Tuesday, August 7
July 30, 2012 08:00 ET
|
Somaxon Pharmaceuticals, Inc.
SAN DIEGO, July 30, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it will release its second quarter financial results...
Somaxon Pharmaceuticals Completes $3.0 Million Registered Direct Offering
July 24, 2012 16:35 ET
|
Somaxon Pharmaceuticals, Inc.
SAN DIEGO, July 24, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has completed its previously announced registered...